Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00720798 · FLOW

Participant flow

An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies · Source last updated 2014-09-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.
    id
    FG000
    title
    Tocilizumab
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        304
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        39
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        129
      type
      Insufficient Therapeutic Response
    4. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Protocol Violation
    5. reasons
      1. group Id
        FG000
        num Subjects
        151
      type
      Refused Treatment
    6. reasons
      1. group Id
        FG000
        num Subjects
        46
      type
      Failure to Return
    7. reasons
      1. group Id
        FG000
        num Subjects
        83
      type
      Reason not Specified
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        2067
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        1311
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        756
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.
    id
    FG000
    title
    Tocilizumab
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        304
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        39
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        129
      type
      Insufficient Therapeutic Response
    4. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Protocol Violation
    5. reasons
      1. group Id
        FG000
        num Subjects
        151
      type
      Refused Treatment
    6. reasons
      1. group Id
        FG000
        num Subjects
        46
      type
      Failure to Return
    7. reasons
      1. group Id
        FG000
        num Subjects
        83
      type
      Reason not Specified
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        2067
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        1311
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        756
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice